George E. Naoum et.al. conducted a study to independently evaluate the impact of axillary surgery type and regional lymph node radiation on breast cancer–related lymphedema rates in patients with breast cancer. The researchers concluded that although regional lymph node radiation adds to the risk of lymphedema, the main risk factor is the type of axillary surgery used.
Eve Maubec et.al. conducted a study to evaluate first-line pembrolizumab monotherapy efficacy and safety in patients with unresectable cutaneous squamous cell carcinomas. The researchers concluded first-line pembrolizumab monotherapy exhibited promising anti-CSCC activity, with durable responses and manageable safety.
Pieternella Johanna Lugtenburg et.al. conducted a study to assess whether rituximab intensification during the first 4 cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone could improve the outcome of these patients compared with standard rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. The researchers concluded that early rituximab intensification during rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone -14 does not improve outcome in patients with untreated diffuse large B-cell lymphoma.
Fabian Knörr et.al. conducted a study to analyze the efficacy of a risk-stratified treatment of children with relapsed anaplastic large cell lymphoma. The researchers concluded that shorter time to relapse was the strongest predictor of subsequent relapse. Allogeneic stem cell transplantation offers a chance for cure in patients with high-risk anaplastic large cell lymphoma relapse.
Loren K. Mell et.al. conducted a study to determine whether intensity modulated radiation therapy could lead to improved tolerance to concurrent cisplatin and gemcitabine for locoregionally advanced cervical cancer. The researchers concluded that intensity modulated radiation therapy can permit higher doses of concurrent gemcitabine with cisplatin and pelvic radiation for locoregionally advanced cervical cancer.
A test that detects changing levels of tumor fragments in the blood may be an easy, non-invasive, and quick way to predict who will benefit from immunotherapy, a treatment option for advanced cancers. Although immunotherapy has been shown to shrink tumors and prolong survival for patients for whom other treatments have failed, about 20-30% of patients benefit from it. Clinicians don't yet know ahead of time who this subset of patients is.
Four stranded DNA structures – known as G-quadruplexes – have been shown to play a role in certain types of breast cancer for the first time, providing a potential new target for personalized medicine, say scientists at the University of Cambridge. In 1953, Cambridge researchers Francis Crick and James Watson co-authored a study published in the journal Nature which showed that DNA in our cells has an intertwined, ‘double helix’ structure. Sixty years later, a team led by Professor Sir Shankar Balasubramanian and Professor Steve Jackson, also at Cambridge, found that an unusual four-stranded configuration of DNA can occur across the human genome in living cells.
A recent study conducted by the experts at Lehigh University demonstrated the effectiveness of a new, innovative machine learning technique to analyze the presence of rare circulating tumor cells (CTCs) in blood. Unlike existing methods, which rely on an expensive and time-consuming process that involves labeling antibodies with fluorescence, this technique uses a powerful label-free detection method.
David Cibula et.al. conducted a study to evaluate sentinel lymph node biopsy without pelvic lymph node dissection in patients with early-stage cervical cancer. The researchers concluded that sentinel lymph node biopsy can achieve high bilateral sentinel lymph node detection in patients with tumours of 4 cm or smaller. At experienced centres, all sentinel lymph node were found in the pelvis, and most were located below the iliac vessel bifurcation.
Julie Arsenault et.al. conducted a study to assess the acute toxicity and quality of life of hypofractionation compared with conventional fractionation for whole breast irradiation after breast-conserving surgery. The researchers concluded that Hypofractionated whole breast irradiation compared with conventional whole breast irradiation resulted in less acute toxicity and improved quality of life.